# Ginkgo Bioworks (DNA) — Earnings

DNA · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/dna/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.75 |
| EPS estimate | −$0.90 |
| EPS surprise | +16.20% |
| Revenue surprise | −16.19% |
| Revenue | $20.2M |
| Revenue estimate | $24.1M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1830214/000162828026054298/dna-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/63745c70-7b75-53bc-a2fd-18c83943c78a.html) |

Ginkgo Bioworks reported Q2 2026 results on August 5, 2026. It posted a loss of $0.75 per share, narrower than the $0.90 loss expected, a 16.20% beat. Revenue of $20.2 million came in 16.19% below the $24.1 million consensus. Compared with Q2 2025, the loss narrowed from $1.10 per share, while revenue fell about 59% from $49.6 million.

Every quarter in the table, back to Q3 2021, was a loss. The annual loss per share narrowed from $51.60 in 2022 to $18.80 in 2023, $10.68 in 2024 and $5.64 in 2025, and Q2 2026 was the smallest quarterly loss shown. Revenue has fallen at the same time. Annual revenue dropped from $477.7 million in 2022 to $169.7 million in 2025, about 64% lower, and the first half of 2026 brought $39.7 million, against $97.9 million a year earlier. Results against estimates have been uneven, with six beats in the last 20 quarters.

Past Q3 reports came between November 6 and November 15. That points to early or mid-November 2026 for the next report, which will show whether losses keep narrowing as revenue runs near $20 million a quarter.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | −$0.90 | −$0.75 | 16.20% | $24.1M | $20.2M |
| Q1 2026 | May 7, 2026 | −$1.21 | −$1.39 | -14.76% | $42.9M | $19.5M |
| Q4 2025 | Feb 26, 2026 | −$1.46 | −$1.41 | 3.09% | $37.1M | $33.0M |
| Q3 2025 | Nov 6, 2025 | −$1.24 | −$1.45 | -16.81% | $38.9M | $38.8M |
| Q2 2025 | Aug 7, 2025 | −$1.57 | −$1.10 | 29.79% | $41.6M | $49.6M |
| Q1 2025 | May 6, 2025 | −$1.53 | −$1.68 | -9.55% | $38.8M | $48.3M |
| Q4 2024 | Feb 25, 2025 | −$1.50 | −$2.00 | -32.98% | $44.5M | $43.8M |
| Q3 2024 | Nov 12, 2024 | −$2.73 | −$1.08 | 60.41% | $45.0M | $89.0M |
| Q2 2024 | Aug 8, 2024 | −$3.10 | −$4.40 | -42.05% | $43.1M | $56.2M |
| Q1 2024 | May 9, 2024 | −$3.33 | −$3.20 | 4.00% | $46.0M | $37.9M |
| Q4 2023 | Feb 29, 2024 | −$3.87 | −$4.40 | -13.79% | $42.5M | $34.8M |
| Q3 2023 | Nov 8, 2023 | −$3.66 | −$6.40 | -75.00% | $48.1M | $55.4M |
| Q2 2023 | Aug 9, 2023 | −$3.45 | −$3.60 | -4.35% | $71.5M | $80.6M |
| Q1 2023 | May 10, 2023 | −$3.40 | −$4.40 | -29.43% | $71.7M | $80.7M |
| Q4 2022 | Mar 1, 2023 | −$8.33 | −$4.00 | 51.95% | $88.6M | $98.3M |
| Q3 2022 | Nov 14, 2022 | −$10.47 | −$16.40 | -56.69% | $60.4M | $66.4M |
| Q2 2022 | Aug 15, 2022 | −$7.33 | −$16.40 | -123.85% | $78.8M | $144.6M |
| Q1 2022 | May 16, 2022 | −$8.56 | −$14.80 | -72.86% | $105.7M | $168.4M |
| Q4 2021 | Mar 28, 2022 | −$1.66 | −$44.00 | -2555.24% | $94.8M | $148.5M |
| Q3 2021 | Nov 15, 2021 | −$1.40 | −$3.20 | -128.57% | $46.0M | $77.6M |

## Frequently Asked Questions

### When did Ginkgo Bioworks (DNA) last report earnings?

Ginkgo Bioworks last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did DNA beat earnings estimates?

Yes. Ginkgo Bioworks reported EPS of −$0.75 for Q2 2026 against a −$0.90 estimate — a 16.20% beat.

### How much revenue did DNA report last quarter?

Ginkgo Bioworks reported $20.2M in revenue for Q2 2026, against a consensus estimate of $24.1M.

## Similar Stocks

- [TWST](https://www.lighthorse.io/tickers/twst) — Twist Bioscience Corporation - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).